What is the clinical evidence from this study?

Study design: Observational. Population: Hypertrophic Cardiomyopathy (n=42). Primary outcome: Major adverse cardiac events (MACE) including death, non-fatal stroke, admission due to CHF, or sustained VT/VF.

What does this research mean for the field?

In a prospective registry of Japanese patients with hypertrophic cardiomyopathy, 24% of patients experienced major adverse cardiac events over a 5-year follow-up period, with significantly worse outcomes observed in those with the dilated phenotype. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

January 1, 2015International Heart JournalOpen Access

Clinical Characteristics and Long-Term Outcomes of Hypertrophic Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Key result

In a prospective registry of Japanese patients with hypertrophic cardiomyopathy, 24% of patients experienced major adverse cardiac events over a 5-year follow-up period.

Population

42 ambulant Japanese patients with hypertrophic cardiomyopathy from the Aichi Hypertrophic Cardiomyopathy…

Design

Cohort

Follow-up

up to 5 years

Authors

MYMasataka YoshinagaFujita Health University DYDaiji YoshikawaFujita Health University HIHideki IshiiInterventional Cardiology

Discussion

Member takes

Implication

Highlights substantial MACE burden in Japanese HCM, especially dilated phenotype; leaves open generalizability and need for prospective validation.

Study Design

Type

Observational (n=42)

Multicenter

Yes

Structured PICO

Population

42 ambulant Japanese patients with hypertrophic cardiomyopathy (HCM) from the Aichi Hypertrophic Cardiomyopathy (AHC) Registry

Outcome

Major adverse cardiac events (MACE), defined as a composite of death, non-fatal stroke, admission due to congestive heart failure (CHF), or episodes of sustained ventricular tachycardia/fibrillation over up to 5 yearscomposite

In a Japanese cohort of HCM patients, 5-year MACE-free survival was 76%, with dilated-HCM patients facing significantly higher risk of adverse events.

Limitations

Relatively small number of patients
Might not represent the characteristics of average Japanese HCM patients or the standard treatment for HCM patients in Japan
Statistical power was not sufficient to detect any significant predictors of MACE
Genetic testing and myocardial biopsy were not necessarily carried out, so other myocardial diseases cannot be ruled out
Selection bias due to including only ambulant patients who had previously been diagnosed with HCM

Cite This Study

Yoshinaga et al. (2015) conducted an observational in Hypertrophic Cardiomyopathy (n=42). In a prospective registry of Japanese patients with hypertrophic cardiomyopathy, 24% of patients experienced major adverse cardiac events over a 5-year follow-up period.

synapsesocial.com/papers/6a1c4921ea84844e355fb098 https://doi.org/10.1536/ihj.14-418

Topics

Heart failure HFrEF treatment Heart failure hospitalization Echocardiography Hypertrophic cardiomyopathy

View Full Paper

Ask AI

Bookmark

Implication

Highlights substantial MACE burden in Japanese HCM, especially dilated phenotype; leaves open generalizability and need for prospective validation.

Clinical Characteristics and Long-Term Outcomes of Hypertrophic Cardiomyopathy

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Topics

Clinical Characteristics and Long-Term Outcomes of Hypertrophic Cardiomyopathy

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider